Professor
Richard
Eastell
MD FRCP FRCPI FRCPEdin FRCPath FMedSci
School of Medicine and Population Health
Professor of Bone Metabolism
Director of the Mellanby Centre for Musculoskeletal Research
+44 114 215 9006
Full contact details
Metabolic Bone Centre, Sorby Wing
Northern General Hospital
- Profile
-
For enquiries, please contact – SMPH-West-Operational@sheffield.ac.uk
I am Professor of Bone Metabolism at the University of Sheffield and Director of the Mellanby Centre for Musculoskeletal Research. My research focuses on understanding osteoporosis and improving its diagnosis, treatment and prevention, with particular interests in bone turnover markers, vertebral fractures and the evaluation of osteoporosis therapies. I graduated in medicine from the University of Edinburgh in 1977 and began research into osteoporosis through a Medical Research Council clinical fellowship in 1978. I subsequently spent five years at the Mayo Clinic, working with Dr B. Lawrence Riggs.I joined the University of Sheffield in 1989, established the metabolic bone service at the Northern General Hospital and became Professor of Bone Metabolism in 1995.My research has helped establish biochemical markers of bone turnover as tools for investigating bone loss and monitoring treatment. I have also developed methods for identifying osteoporotic vertebral fractures, including morphometric and algorithm-based qualitative approaches. Working with colleagues internationally, I have contributed to pivotal trials establishing the efficacy and safety of treatments including risedronate, zoledronic acid and denosumab, and to clinical guidelines for osteoporosis and other metabolic bone disorders.Through the Foundation for the National Institutes of Health–American Society for Bone and Mineral Research SABRE programme, I have helped establish treatment-related change in total hip bone mineral density as a surrogate endpoint for fracture reduction. In December 2025, the US Food and Drug Administration qualified this endpoint for trials of new treatments for postmenopausal women with osteoporosis at risk of fracture. This advance supports more efficient trials and the development of new therapies.I directed Sheffield’s NIHR Biomedical Research Unit in Musculoskeletal Medicine from 2008 to 2012. I am a Fellow of the Academy of Medical Sciences and an NIHR Emeritus Senior Investigator, and have served as President of the Bone Research Society and the European Calcified Tissue Society.I have supervised 38 PhD, 6 MD, and 5 MPhil students. My publication record includes 667 articles, with more than 72,000 citations recorded in Web of Science in August 2026. My contributions have been recognised by the American Society for Bone and Mineral Research through the Frederick C. Bartter Award for clinical investigation in 2014 and the William F. Neuman Award in 2023.
- Research interests
-
My research focus is osteoporosis. The University of Sheffield is well regarded for its contribution to the study of osteoporosis. I have been ranked the third most highly-cited researcher in the world in the field of osteoporosis (Pluskiewicz W, et al. Arch Osteoporos. 2018 Mar 26;13(1):35). I study the epidemiology, pathogenesis, diagnosis and treatment of the disease. This has involved developing and establishing assays for bone turnover markers and studying their clinical utility. I have developed new approaches to the definition of vertebral fracture and applied new approaches such as vertebral fracture assessment. I have developed tools to evaluate bone strength such as high-resolution quantitative computed tomography, ultrasound and finite element modelling of bone strength. I have evaluated the endocrine changes in osteoporosis to better understand its causes. I have designed and conducted clinical trials of nutrition and drugs for the prevention and treatment of osteoporosis. I have evaluated approaches to enhance compliance with treatment.
Current projects:
• Anabolic effects of teriparatide on bone
• The onset and offset of bisphosphonates on bone
• Determinants of peak bone mass
• Hypophosphatasia
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic. Bone, 144. View this article in WRRO
- Treatment‐related changes in bone turnover and fracture risk reduction in clinical trials of antiresorptive drugs: proportion of treatment effect explained. Journal of Bone and Mineral Research, 36(2), 236-243.
- Establishing race-, gender- and age-specific reference intervals for pyridoxal 5’-phosphate in the NHANES population to better identify adult hypophosphatasia. Bone, 141. View this article in WRRO
- Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. New England Journal of Medicine, 383(8), 743-753. View this article in WRRO
- Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. The Lancet Diabetes & Endocrinology, 8(8), 672-682.
- Normocalcemic hyperparathyroidism : study of its prevalence and natural history. The Journal of Clinical Endocrinology & Metabolism, 105(4). View this article in WRRO
- Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. The Journal of Clinical Endocrinology & Metabolism, 105(3), 587-594.
- Quantitative computed tomography discriminates between postmenopausal women with low spine bone mineral density with vertebral fractures and those with low spine bone mineral density only: the SHATTER study. Osteoporosis International, 31(4), 667-675. View this article in WRRO
- The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. Bone, 131. View this article in WRRO
- Association between drug treatments for patients with osteoporosis and overall mortality rates : a meta-analysis. JAMA Internal Medicine, 179(11).
- Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT Extension I trials. Journal of Bone and Mineral Research, 34(5), 810-816. View this article in WRRO
- Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. Journal of Bone and Mineral Research, 33(4), 634-642. View this article in WRRO
- Management of endocrine disease: modern spectrum of bone turnover markers: are they clinically useful?. European Journal of Endocrinology, 178(1), R19-R31. View this article in WRRO
- Bone Density, Microstructure and Strength in Obese and Normal Weight Men and Women in Younger and Older Adulthood. Journal of Bone and Mineral Research, 30(5), 920-928. View this article in WRRO
- Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. The Lancet Oncology, 15(13), 1460-1468.
- Proton pump inhibitor use and the antifracture efficacy of alendronate.. Arch Intern Med, 171(11), 998-1004.
- Lasofoxifene in postmenopausal women with osteoporosis.. N Engl J Med, 362(8), 686-696.
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. NEW ENGL J MED, 361(8), 756-765.
- The effects of tibolone in older postmenopausal women. NEW ENGL J MED, 359(7), 697-708.
- Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.. J Clin Oncol, 26(7), 1051-1057.
- Effect of risedronate on the risk of hip fracture in elderly women. NEW ENGL J MED, 344(5), 333-340.
- Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. OSTEOPOROSIS INT, 11(1), 83-91.
- Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial.. BMJ, 315(7118), 1255-1260.
All publications
Journal articles
- Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic. Bone, 144. View this article in WRRO
- Treatment‐related changes in bone turnover and fracture risk reduction in clinical trials of antiresorptive drugs: proportion of treatment effect explained. Journal of Bone and Mineral Research, 36(2), 236-243.
- Establishing race-, gender- and age-specific reference intervals for pyridoxal 5’-phosphate in the NHANES population to better identify adult hypophosphatasia. Bone, 141. View this article in WRRO
- Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. New England Journal of Medicine, 383(8), 743-753. View this article in WRRO
- Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. The Lancet Diabetes & Endocrinology, 8(8), 672-682.
- Normocalcemic hyperparathyroidism : study of its prevalence and natural history. The Journal of Clinical Endocrinology & Metabolism, 105(4). View this article in WRRO
- Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. The Journal of Clinical Endocrinology & Metabolism, 105(3), 587-594.
- Quantitative computed tomography discriminates between postmenopausal women with low spine bone mineral density with vertebral fractures and those with low spine bone mineral density only: the SHATTER study. Osteoporosis International, 31(4), 667-675. View this article in WRRO
- The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. Bone, 131. View this article in WRRO
- Association between drug treatments for patients with osteoporosis and overall mortality rates : a meta-analysis. JAMA Internal Medicine, 179(11).
- Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT Extension I trials. Journal of Bone and Mineral Research, 34(5), 810-816. View this article in WRRO
- Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. Journal of Bone and Mineral Research, 33(4), 634-642. View this article in WRRO
- Management of endocrine disease: modern spectrum of bone turnover markers: are they clinically useful?. European Journal of Endocrinology, 178(1), R19-R31. View this article in WRRO
- Bone Density, Microstructure and Strength in Obese and Normal Weight Men and Women in Younger and Older Adulthood. Journal of Bone and Mineral Research, 30(5), 920-928. View this article in WRRO
- Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. The Lancet Oncology, 15(13), 1460-1468.
- Proton pump inhibitor use and the antifracture efficacy of alendronate.. Arch Intern Med, 171(11), 998-1004.
- Lasofoxifene in postmenopausal women with osteoporosis.. N Engl J Med, 362(8), 686-696.
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. NEW ENGL J MED, 361(8), 756-765.
- The effects of tibolone in older postmenopausal women. NEW ENGL J MED, 359(7), 697-708.
- Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.. J Clin Oncol, 26(7), 1051-1057.
- Effect of risedronate on the risk of hip fracture in elderly women. NEW ENGL J MED, 344(5), 333-340.
- Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. OSTEOPOROSIS INT, 11(1), 83-91.
- Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial.. BMJ, 315(7118), 1255-1260.
- Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic. Bone, 144. View this article in WRRO
- Research group
-
Current Collaborators
- Professor Bo Abrahamsen
- Professor Nick Bishop
- Dr Dennis Black
- Dr Richard Jacques
- Professor Cyrus Cooper
- Dr Steven Cummings
- Dr Paul Dimitri
- Pefessor Claus Gluer
- Dr David Hughes
- Professor Eugene McCloskey
- Dr Paul Miller
- Dr Nicola Peel
- Professor Graham Russell
- Professor Mark Wilkinson
- Professor Graham Williams
Postgraduate Students
- Ankita Duseja
- Patryk Zarecki
- Teaching interests
-
I teach medical students and oversee B. Med. Sci. projects. I teach on a number of postgraduate courses as well as giving invited lectures.
- Professional activities and memberships
-
I am an Emeritus Senior Investigator of the NIHR, a Fellow of the Academy of Medical Sciences. I am past president of the European Calcified Tissue Society, the Bone Research Society and past chairman of the National Osteoporosis Society. I am Senior Editor of the journal 'Bone'.